Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de Mexico, Ciudad Universitaria, Mexico City 04510, Mexico.
Cells. 2024 Jun 26;13(13):1107. doi: 10.3390/cells13131107.
Human papillomavirus (HPV)-positive Head and Neck Squamous Cell Carcinomas (HNSCC) comprise a particular cancer entity traditionally associated with better clinical outcomes. Around 25% of HNSCC are HPV positive, HPV16 being the most prevalent type. Nevertheless, close to 30% of the HPV-positive patients have an unfavorable prognosis, revealing that this type of tumor exhibits great heterogeneity leading to different clinical behaviors. Efforts have been made to identify RNA molecules with prognostic value associated with the clinical outcome of patients with HPV-positive HNSCC, with the aim of identifying patients at high risk of metastasis, disease recurrence, and poor survival, who would require closer clinical follow-up and timely intervention. Moreover, the molecular identification of those HPV-positive HNSCC patients with good prognosis will allow the implementation of de-escalating therapeutic strategies, aiming to reduce side effects, resulting in a better quality of life. This review compiles a series of recent studies addressing different methodological and conceptual approaches aimed at searching for potential gene expression-based biomarkers associated with the prognosis of patients with HPV-positive HNSCC.
人乳头瘤病毒（HPV）阳性的头颈部鳞状细胞癌（HNSCC）是一种特定的癌症实体，传统上与更好的临床结果相关。约 25%的 HNSCC 为 HPV 阳性，其中 HPV16 最为常见。然而，近 30%的 HPV 阳性患者预后不良，这表明这种肿瘤具有很大的异质性，导致不同的临床行为。人们已经努力识别与 HPV 阳性 HNSCC 患者临床结果相关的具有预后价值的 RNA 分子，目的是识别具有高转移、疾病复发和不良生存风险的患者，这些患者需要更密切的临床随访和及时干预。此外，对那些预后良好的 HPV 阳性 HNSCC 患者进行分子鉴定，将有助于实施降级治疗策略，旨在减少副作用，从而提高生活质量。本综述汇集了一系列最近的研究，这些研究探讨了不同的方法学和概念方法，旨在寻找与 HPV 阳性 HNSCC 患者预后相关的潜在基于基因表达的生物标志物。
